Livzon Pharmaceutical Group Inc
SZSE:000513
Livzon Pharmaceutical Group Inc
Cost of Revenue
Livzon Pharmaceutical Group Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
Cost of Revenue
-¥4.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-¥6.1B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥3.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥28.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Cost of Revenue
-¥1.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Livzon Pharmaceutical Group Inc
Glance View
Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.
See Also
What is Livzon Pharmaceutical Group Inc's Cost of Revenue?
Cost of Revenue
-4.2B
CNY
Based on the financial report for Sep 30, 2024, Livzon Pharmaceutical Group Inc's Cost of Revenue amounts to -4.2B CNY.
What is Livzon Pharmaceutical Group Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
Over the last year, the Cost of Revenue growth was 12%. The average annual Cost of Revenue growth rates for Livzon Pharmaceutical Group Inc have been 1% over the past three years , -4% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet